{"nctId":"NCT04924062","briefTitle":"Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study","startDateStruct":{"date":"2020-07-10","type":"ACTUAL"},"conditions":["Biliary Tract Carcinoma"],"count":158,"armGroups":[{"label":"Arm A (Pembrolizumab+Gemcitabine+Cisplatin)","type":"EXPERIMENTAL","interventionNames":["Biological: Pembrolizumab","Drug: Gemcitabine","Drug: Cisplatin"]},{"label":"Arm B (Placebo+Gemcitabine+Cisplatin)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Gemcitabine","Drug: Cisplatin","Drug: Placebo"]}],"interventions":[{"name":"Pembrolizumab","otherNames":["MK-3475"]},{"name":"Gemcitabine","otherNames":["Gemzar"]},{"name":"Cisplatin","otherNames":["Platinol®","Platinol®-AQ"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n* Has histologically confirmed diagnosis of advanced (metastatic) and/or unresectable (locally advanced) biliary tract cancer (intra-or extrahepatic cholangiocarcinoma or gallbladder cancer)\n* Has measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST 1.1), as determined by the site investigator\n* Participants with a history of hepatitis B or hepatitis C can be enrolled if they meet study criteria\n* Is able to provide archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion\n* Has a life expectancy of greater than 3 months\n* Has adequate organ function\n\nExclusion Criteria\n\n* Has had previous systemic therapy for advanced (metastatic) or unresectable (locally advanced) biliary tract cancer (intra-or extra hepatic cholangiocarcinoma or gallbladder cancer)\n* Has ampullary cancer\n* Has small cell cancer, neuroendocrine tumors, lymphoma, sarcoma, mixed tumor histology and/or mucinous cystic neoplasms\n* Has received prior therapy with an anti-programmed cell death 1 (anti-PD-1), anti- programmed cell death ligand 1 or 2 (anti-PD-L1, anti-PD-L2) agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated protein 4 \\[CTLA-4\\], OX-40, CD137)\n* Has a known history of, or any evidence of, central nervous system (CNS) metastases and/or carcinomatous meningitis, as assessed by local site investigator\n* Has had an allogenic tissue/solid organ transplant","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival (OS)","description":"Overall survival was defined as the time from randomization to death due to any cause. Per protocol the final reported outcome for OS did not include any sensitivity or supportive analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.1","spread":null},{"groupId":"OG001","value":"9.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival (PFS) Per RECIST 1.1 as Assessed by BICR","description":"Progression-free survival was defined as the time from randomization to the first documented disease progression or death due to any cause, whichever occurred first.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":null},{"groupId":"OG001","value":"5.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)","description":"ORR was defined as the percentage of participants who had a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: a ≥30% decrease in the sum of diameters \\[SOD\\] of target lesions) as assessed by BICR per RECIST 1.1, which was adjusted for this study to allow a maximum of 10 target lesions in total and 5 per organ.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.0","spread":null},{"groupId":"OG001","value":"28.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR","description":"For participants who demonstrated a confirmed CR or PR, DOR was the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurred first.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","spread":null},{"groupId":"OG001","value":"5.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Experience One or More Adverse Events (AE)","description":"An adverse event (AE) was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurred during the course of the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"82","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Discontinued Study Intervention Due to an Adverse Event (AE)","description":"An AE was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurred during the course of the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":28,"n":74},"commonTop":["Anaemia","White blood cell count decreased","Neutrophil count decreased","Platelet count decreased","Nausea"]}}}